Assistance Publique Hopitaux De Paris
Verified site
Paris, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial involves people with rare lysosomal disorders such as GM1 gangliosidosis, GM2 gangliosidosis, Niemann-Pick disease type C, and Gaucher disease type 3. These conditions affect the cell’s recycling system, causing harmful material to build up. Participants will receive the oral medication nizubaglustat (code name AZ-3102) in the form of an orodispersible tablet, which dissolves in the mouth.
The study aims to assess the long‑term safety and tolerability of continued daily use of the medication. Safety will be monitored by checking for side effects, changes in vital signs such as blood pressure and heart rate, and routine blood tests that look at blood cells, clotting, and chemistry. Blood samples will also be used to measure specific markers that reflect disease activity for each condition.
After giving informed consent, participants will take the study drug each day for an extended period, with regular clinic visits where health status and laboratory results are reviewed. The schedule includes periodic assessments over many months to observe how the body responds over time. No additional experimental procedures are required beyond the standard monitoring visits.
The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
4 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Paris, France
Gothenburg, Sweden
Hochheim Am Main, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Nizubaglustat is an experimental oral medication that comes in a tablet that dissolves in the mouth. It is being studied in people with rare lysosomal disorders, which are conditions where the body’s cells cannot break down certain substances properly. In this trial, participants who have already taken the drug in earlier studies continue to take it each day to help researchers learn how safe it is over a longer period and how well people can tolerate it. The drug is considered an orphan drug, meaning it is intended for a very small number of patients with these rare diseases.
A rare inherited disorder in which the fatty molecule GM1 builds up inside cells, especially in the brain and other tissues. This accumulation leads to gradual loss of motor skills, coordination problems, and enlargement of the liver and spleen. Symptoms typically appear in infancy or early childhood and become more pronounced over time.
A group of rare genetic conditions, including Tay‑Sachs and Sandhoff disease, where the fatty substance GM2 accumulates in nerve cells. The buildup causes a steady decline in movement abilities, vision, and mental function. The disease usually starts in infancy or early childhood and worsens progressively.
A rare genetic disorder that impairs the transport of cholesterol and other lipids, leading to their storage in the brain, liver, and spleen. Over time this causes worsening balance problems, difficulty with movement, and a gradual decline in thinking abilities. Symptoms can begin in childhood or later, and they slowly become more severe.
The chronic form of Gaucher disease in which fatty substances accumulate in the spleen, liver, bone, and sometimes the brain. It leads to gradual organ enlargement, bone pain, and increasing difficulty with movement. Signs usually emerge in childhood or adolescence and progress slowly over many years.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.